Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Koninklijke Philips NV — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Koninklijke Philips NV trades at $24.22 (market cap $23.52B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays a 4.17% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Koninklijke Philips NV for 84 Days on average.
| HALO | PHG | |
|---|---|---|
Market Cap | $12.58B | $23.52B |
Volume | 2,179,278 | 1,635,069 |
Sector | Health | Health |
52-Week High | $115.22 | $32.91 |
52-Week Low | $61.63 | $23.81 |
Typical Hold Time | 1 Days | 84 Days |
Enterprise Value | $14.49B | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PHG trades at $24.24, up 0.62% today, amid a bearish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Recent financials show a return to profitability in 2025 with net income of $895 million, while cash flow from operations remains positive at $1.17 billion. Key developments include new product launches in healthcare imaging and a $33.7 million ARPA-H award for AI-enabled stroke care.
The outlook is mixed: strong earnings momentum and solid profitability metrics support upside, but technical weakness and a high 'Hold' analyst consensus suggest near-term caution. Risks include competitive pressures and debt levels, though institutional buying activity indicates underlying confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
